Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BRIEF-Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T‑cells

By: Reuters: Company News
* Adaptimmune Therapeutics Plc - initiated study of NY-ESO SPEAR T-cells targeting NY-ESO in combination with keytruda in patients with multiple myeloma
Related Stocks:
Adaptimmune Ther ADR Gsk Plc ADR Merck & Co
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.